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Abstract 
 
Dementia is a collection of symptoms associated with impaired cognition and impedes everyday 
normal functioning. Dementia, with Alzheimer’s disease constituting its most common type, is highly 
complex in terms of etiology and pathophysiology. A more quantitative or computational attitude 
towards dementia research, or more generally in neurology, is becoming necessary – Computational 
Neurology. We provide a focused review of some computational approaches that have been 
developed and applied to the study of dementia, particularly Alzheimer’s disease. Both mechanistic 
modeling and data-driven, including AI or machine learning, approaches are discussed. Linkage to 
clinical decision support systems for dementia diagnosis will also be discussed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Neurology is a subdiscipline of medicine which seeks to understand and treat disorders of the nervous 
system. Many neurological or neurodegenerative diseases are often age-dependent, incurable or 
debilitating, while placing increasingly enormous socioeconomic burdens [45,23]. In particular, 
dementia is a collection of symptoms that is associated with impairment in cognition, particularly 
memory functioning, and impedes everyday normal functioning [20].  
 
Alzheimer’s disease (AD) is the most common form of dementia, and symptoms may involve memory 
and language impairment [20]. AD can be categorized under as familial AD (family history of the 
disease) and sporadic AD, with the latter overwhelmingly the most common type [17]. Various genes 
are currently thought to be associated with these different AD types. Mutations in amyloid precursor 
protein (APP), presenilin-1 (PSEN1) and presenilin-2 (PSEN2) are associated with familial AD while 
Apolipoprotein E (ApoE) gene has been linked to the sporadic type [20]. Other types of dementia 
include vascular dementia, frontotemporal dementia, Lewy body dementia, Huntington’s disease, and 
Creutzfeldt-Jakob disease [20]. The intermediate stage between healthy and AD is labelled mild 
cognitive impairment (MCI) [20]. However, MCI is a loosely defined and heterogenous group, 
consisting of non-neurodegenerative or non-AD converters and people with other illnesses e.g. 
psychiatric illness [20]. Co-morbidities with other neurological disorders or illnesses, e.g. with epilepsy 
[42], are also well documented. With age as the primary risk factor, diagnosing and treating dementia 
and AD are now reaching a level of increasing urgency, not only because of the high proportion of 
cases relative to other neurodegenerative diseases, but also due to the rising global population and 
average lifespan [45,20].  
 
To identify mechanisms and factors associated with AD, and its treatments, basic science and 
preclinical studies are necessary. Current preclinical models of AD pathologically associate the disease 
with beta-amyloid plaques (protein fragment snipped from an amyloid precursor protein) or tau 
neurofibrillary tangles (aggregates of hyperphosphorylated tau protein) formed in the brain in specific 
locations [20]. As the disease progresses, increasing evidence has shown that tau can spread from 
subcortical brain regions, particularly the entorhinal cortex and hippocampal region, to the rest of the 
brain regions via the connections between neurons i.e. synapses [9]. As tau is known to be toxic to 
synapses, it can cause damage to the connections as it propagates. A more recent model of AD 
associates it with neuroinflammation via abnormal glial cell activation [8].  
 
Although there had been many potential AD drug developments in the pipeline, especially targeting 
beta-amyloids, they have mainly led to underwhelming results [32,11]. Currently US Food and Drug 
Administration (FDA) approved drugs such as acetylcholinesterase inhibitors are targeted to slow 
certain symptoms of cognitive decline, but not halting or curing AD [11]. A key challenge is the lack of 
surrogate biomarkers of AD for clinical studies. An example of surrogate markers for cardiovascular 
disease would be elevated cholesterol levels. Hence, the etiology and pathophysiology of AD remain 
to be completely characterized. Another challenge is the type of model. In particular, rodent models 
of AD, used in preclinical studies lack sufficient comparative research work linking them to human AD 
[18]. As we shall later discuss, computational models in the field of Computational Neuroscience may 
not only shed light on the complexity of the disease, and its co-morbidities, but also offer a bridge 
across species.  
 
From a practical perspective, regardless of the etiology and pathophysiology, there is an urgent need 
to make informed clinical decisions for diagnosis and prognosis to allow appropriate care and 
treatment. For instance, AD or dementia is currently underdiagnosed (see e.g. [31]) and the 
misdiagnosis rates are seemingly high [21], as medical doctors or physicians in primary care may not 
be sufficiently or appropriately well trained to detect the disease within their limited consultation time 
[6]. As we shall discuss below, data-driven computational, statistical or artificial intelligence (AI) 
models may help in not only mapping the relationships across symptoms and markers, but also act as 
clinical decision support systems by providing more objective and standardized information regarding 
AD status or progression.  
 
Training or developing such computational or statistical models would require the availability of high 
quality and relevant attributes in datasets. However, in many clinical studies, cohorts are often small 
and selective. Datasets are also usually not openly available. Nevertheless, recent efforts and 
initiatives have moved towards larger scale studies, and big data integration and curation. Notable 
initiatives include the Alzheimer’s Disease Neuroimaging Initiative (ADNI), the National Alzheimer’s 
Coordinating Center (NACC), and the Dementias Platform UK (DPUK). Importantly, these open 
datasets now enable researchers, particularly, those with a computational or theoretical incline, to 
perform large-scale quantitative analyses to enable bigger research impact.  
 
In the rest of this review, we shall focus on discussing how quantitative and computational approaches 
can be applied to address some of the aforementioned issues. We termed such approaches under the 
umbrella of Computational Neurology. We shall divide the discussions into three sections, focusing on 
AD, and each with a case study based on our previous work. The first section will discuss mechanistic 
modeling through Computational Neuroscience, and the second section will be on data-driven and AI 
approaches. Fig. 1 summarizes these computational approaches. The final section will provide a brief 
summary and the opportunities for further work.  
 
 
Fig. 1. Schematic of computational and theoretical approaches in Computational Neurology. Blue boxes: Small 
or focused data; brown: larger or more heterogeneous data. Arrows: Relationships. Sometimes AI, data mining 
and machine learning methods are also used in relatively smaller or less heterogeneous data (grey arrow) to 
guide mechanistic modeling (not shown).  
 
 
Computational Neuroscience: Mechanistic Modeling Approaches 
 
If one is allowed to think of brain functions as some form of computational processing (though not 
necessarily processing like a computer, the understanding of brain functions can be divided into three 
levels of description (Marr, 1982) [33]. The first level is the computational theory, which deals with 
the goal of neural computation. This involves the appropriateness and logic of the strategy in the 
computation. The second level is the representations and algorithms of the processing. This entails 
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how the computation is implemented or realized, what the inputs and outputs are, and the algorithms 
that process them. The third level is the “hardware” implementation, which describes how the 
representations and algorithms are represented in physical (e.g. biological) systems. The level to be 
employed depends on the research questions and also the availability of data types.  
 
The field of Computational Neuroscience or Theoretical Neuroscience encompasses all these levels of 
description on brain functions [14]. In particular, the biophysical mechanistic understanding 
underlying neurodegeneration such as dementia can be enhanced with biophysically realistic or 
biologically motivated computational models [19,10]. Such models incorporate biological and 
physiological information of specific brain system(s) and apply mathematical modeling, especially 
differential equations to describe the systems’ dynamics. Hence, the analyses of such models are often 
closely linked to dynamical systems theory [26,44]. Models often involve so-called conductance-based 
models, building on Hodgkin-Huxley type models [24], which make use of mathematical descriptions 
of ion-channel dynamics associated with neuronal excitability [28]. When the neurons in the models 
are “coupled” via mathematical description of their associated synaptic dynamics, neuronal circuit 
models can be simulated and studied. Hence, such models can, in principle, allow description across 
multiple levels, such as from ion channel dynamics through neuronal circuit dynamics to specific set 
of cognitive (e.g. memory) functions – multiscale modeling. It is the hope that cognition in normal and 
abnormal brains can be understood through modeling and simulation of neuronal circuit functions.  
 
As an example, we have previously mentioned that the hippocampal brain region (Fig. 2A) is known 
to be one of the regions of deterioration in early-stage AD. The deterioration was associated with 
dysfunctions in memory, navigation and cognition, often observed in AD [20]. To investigate the 
possible mechanism of how beta-amyloid plaques can affect the activity and function of this region, a 
biophysical computational model of the hippocampal septal neuronal circuit model was modeled and 
simulated (Fig. 2B) [48,49].  
 
     
 
Fig. 2. Neuronal circuit model and simulations. A. Locations of the hippocampus and (medial) septum in the 
human brain. B. Neuronal circuit architecture of four populations of neurons in the hippocampal septal region. 
Excitatory (inhibitory) synapses: brown (black) filled circled-head arrows. Only the CA1 part of the hippocampus, 
and the medial part of the septum were modeled. C. Timecourse of neuronal membrane potential dynamics and 
spiking activities of a sample neuron from each neuronal population. Vertical dotted lines: Boundaries of 
rhythmic activity phases. D. Change in power spectra of neuronal population activity as conductance of A-type 
current, gA, decreases. Higher frequency band peak increases while lower frequency band peak decreases. E. A 
hypothetical demonstration of neuronal hyperexcitability on memory deficits and epilepsy. Top: Spike raster 
gram of 10 modeled neurons. Correct memory pattern represented by pyramidal neurons 1, 3-5, 7, 9 and 10 
using the original gA condition. Middle: Memory recall disrupted by low gA induced hyperexcitability due to 
additional neuronal spiking activity by the previously inactivated neurons (2 and 8). Bottom: Further 
hyperexcitation of pyramidal neurons lead to signs of epileptic seizure – comorbidity. A. Adopted with 
permission from [43]. B. Adapted with permission from [48]. D(right). C-E. Adapted with permission from [49].  
 
 
In [48], a conductance-based Hodgkin-Huxley type neuronal model was developed to mimic the 
spiking activity of four types of hippocampal septal neurons, namely, the excitatory pyramidal 
neuronal types, and three inhibitory neuronal types (OLM, MSGABA, and Basket cells). The two-
compartmental pyramidal neuronal membrane potential consists of a cell body called the soma, 
coupled to an extended part of the cell called dendrite in which other neurons can connect to 
excite/inhibit. The membrane potential dynamics were described by:  
 
 
 
 
 
where subscript soma and dendrite denoted soma and dendrite, respectively. Ie was some injected DC 
current and Isyn’s were the summed synaptic currents. gc was the coupling strength between the soma 
and dendrite while p was some fixed parameter. The rest of the I’s represent various ion-channel 
currents (with the types denoted as subscripts) based on the Hodgkin-Huxley type formalism with 
dynamics described by first-order kinetics (for details, see [48]). Many of the model parameters were 
constrained by neurophysiological data. For simplicity, the other three inhibitory neurons were 
modeled using one-compartment model (i.e. one differential equation describing each neuronal 
membrane dynamics), again consisting of various ion channel currents [48]. At baseline (control 
condition), the simulated neuronal spiking activities resembled those observed in experiments (Fig. 
2c).  
 
Based on several previous experimental studies, various ion-channel currents were altered in the 
model to indirectly simulate the effects of beta-amyloid plaques on the neuronal circuit. It was found 
that plaque-inhibited A-type fast-inactivating potassium ion channel current, IA, can induce a 
significant effect on the neuronal population network dynamics [48]. Moreover, by analyzing the 
summed membrane potential dynamics, as IA decreases (via reduction in its conductance, gA), lower 
frequency band power decreases while that of higher frequency band power increases (Fig. 2D) 
[48,49]. This was consistent with experimental observations (see e.g. [48,49] for some of the 
experimental findings described therein). The increase in oscillation band power was found to be due 
to the enhanced synchrony of the pyramidal neurons, while the decrease was due to the spiking phase 
relationship among the different neuronal types [49]. Interestingly, as the IA current was gradually 
inhibited (by beta-amyloid plaque), the hyperexcited pyramidal neurons first partially 
misremembered some earlier encoded information (cf. Figs. 2E (a) and (b)). Then with even higher 
hyperexcitation in the network, the latter exhibited sign of seizure (Fig. 2E (c)), as found in some AD 
patients – co-morbidity [42].  
 
To summarize, mechanistic neuronal circuit modeling could help reveal specific downstream biological 
features (e.g. ion channels) affected by beta-amyloid plaques and provide a mechanistic explanation 
of the non-trivial changes in neuronal network dynamics. Such modeling could link mechanisms of co-
morbidities (e.g. AD and epileptic seizures). Importantly, these models offer predictions that can be 
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tested experimentally, e.g. between neuronal firing homeostasis and AD [1,41]. The models, usually 
described by differential/difference equations (or state maps), can be rigorously mathematically 
analyzed using applied dynamical systems theory (not shown, but see [49]). Moreover, models such 
as these can also (partially) address the issue of linking preclinical to clinical studies, with appropriate 
changes in the model parameters – the governing equations are largely similar.  
 
Simpler (or more abstract) mechanistic models such as integrate-and-fire neuronal models [14,26,1] 
can also be employed if the neuronal excitability biophysical details (i.e. neuronal ion-channel 
dynamics) do not form part of the research questions. Similarly, population level (neural mass or 
mean-field) type models are also useful for AD investigation [4]. Other levels of modeling [33], 
especially at the computational cognitive level of description, include probabilistic, statistical, and 
information-theoretic types (see e.g. [14]) (Fig. 1). Again, these computational and theoretical tools 
are especially useful if biophysical details are not as important or readily available with respect to the 
research questions to be addressed.  
 
 
Data-Driven and AI Approaches 
 
With the availability of neuroimaging technology and data, more direct analyses on the 
neurobiological progression of neurodegeneration in humans have become possible. For AD or 
dementia, (structural) magnetic resonance imaging (MRI), computed tomography (CT), and positron 
emission tomography (PET) scans are used as part of the clinical care pathway [34]. In academic 
communities, functional neuroimaging such as functional MRI (fMRI), electroencephalography (EEG), 
and more recently magnetoencephalography (MEG), are additionally used. The analyses of 
neuroimaging data are now providing a growing arena for the application of data-driven artificial 
intelligence (AI) techniques, and more recently, a subclass of AI called machine learning (ML) [46,2,13]. 
This is in parallel with (forward) model-driven analyses such as the neurobiologically based dynamic 
causal modeling (see e.g. [40,38]) or the more abstract oscillator-based modeling (e.g. [50]).  
 
ML, applied to biomedical and healthcare data, mostly falls into the categories of supervised or 
unsupervised learning [36,37]. Supervised learning requires known labels or targets (e.g. disease 
classes), while unsupervised learning does not require such a priori knowledge. ML not only can 
provide more automation to analyses but may also offer higher classification accuracy of disease 
stage. For example, making use of their prowess in image processing, deep learning (deep neural 
network) models can remarkably now detect AD at around 96% accuracy and 84% for predicting 
conversion from MCI to AD [27].  
 
ML can also make use of the integration of different neuroimaging modalities, taking advantage of 
their complementary strengths, to improve disease classification [39]. For example, using multi-kernel 
learning (MKL; for learning to identify an optimal kernel from a linear combination of kernels) with 
DARTEL (diffeomorphic anatomical registration through exponential Lie algebra) algorithm (for 
enhancing anatomical registration), [47] demonstrated that combined PET (with tracer PiB; Pittsburgh 
compound B) and MRI (grey matter, GM) data could enhance prediction of the three two-class 
classifications (using support vector machine): AD-vs-healthy (95.7%), MCI-vs-healthy (95.8%), and 
AD-vs-MCI (95.1%), as compared to using only PiB-PET (81.6%, 90.7%, 79.6%, respectively) or GM 
(91.3%, 92.5%, 89.1%, respectively). Similarly, using the leave-one-out cross-validation approach, a 
conservative and more clinically relevant approach, regression analyses on the multi-modal data for 
predicting individuals in AD, MCI or healthy classes provide a coefficient of determination of r2=0.86, 
as compared to lower values using PiB-PET (r2=0.61) or MRI (r2=0.72) data alone (Fig. 3). The ML 
approach is sufficiently general to incorporate other non-neuroimaging data.  
 
 
Fig. 3. A machine learning framework based on multi-kernel learning (MKL) and DARTEL algorithms for 
predicting AD. A. Framework that allows combination of multiple neuroimaging modalities (MRI, PET). B,C. A 
line prediction plot (predictions overlaid on targets) of diagnostic values of participants derived from: (GM-)MRI, 
(PiB-)PET scans, modeled by kernel ridge regression (KRR) method, and combined GM-MRI and PiB-PET data 
modeled by an optimized MKL technique, simpleMKL (or sMKL). Proximity of sample data to any horizontal line 
denotes the likelihood of classifying under that particular diagnostic category associated with that line. B. Group 
level; C. individual level with individual who transitioned across the classes (arrows). Adapted with permission 
from [47].  
 
 
To date, several AI/ML approaches in AD research studies have focused on neuroimaging data. This is 
not too surprising, given the latter’s complexity. However, other data types are gradually being 
investigated using ML. In clinical practice, most data consist of patients’ electronic health/medical 
records such as medical history, family history, cognitive and functional assessments and 
sociodemographic, and typical blood-based tests. However, (typically structural) neuroimaging is 
conducted only if there is sufficient evidence of cognitive decline to warrant that, or to assist with 
distinguishing dementia subtypes (see e.g. [34,15]). Further, some of these non-imaging data can be 
readily collected longitudinally and in large quantities (big data). This would allow better 
understanding of the disease and its progression.  
 
However, these data are usually highly heterogeneous (variety of data types) with multiple missing 
levels of description, e.g. data including specific genotype and memory recall performance. Hence, it 
is not practical or possible to develop mechanistic computational models based on such data. Hence, 
(big) data analytical approaches are more appropriate [25]. Often, these data have a large number of 
data features (i.e. variables, or sometimes called attributes or dimensions). These may require 
performing feature selection or dimensional reduction with e.g. supervised or unsupervised learning 
[22] to allow further in-depth analyses while reducing the risk of model overfitting. Such methods 
include information gain or recursive feature elimination types (e.g. [22,16,7]).  
 
With the complexity of AD, data analytical approaches can holistically capture the relationship across 
multiple data features, for example, using probabilistic graphical modeling [30]. In particular, Bayesian 
network modeling, a specific type of directed acyclic graphical modeling of conditional 
dependences/probabilities (reflected as edges in a graph), is easy to use and interpret without too 
many assumptions [30,5]. For example, using an open dataset from the Australian Imaging Biomarkers 
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and Lifestyle Study of Ageing (AIBL), [16] made use of Bayesian network modeling to capture the 
probabilistic causal relationship between very different data types as diverse as age, genotype, 
cognitive and functional assessments, and coarse-grained (total volume) neuroimaging data.  
 
The Bayesian networks in [16] were generated using Hill Climbing score-based learning technique, in 
which network configurations with the highest score were selected [12]. Clinical dementia rating (CDR) 
score was used as the AD stage/class instead of using the more subjective clinical diagnosis. 
Interestingly, while following the same group of participants over two time points, it was found that 
the relationship can change over time, perhaps reflecting the dynamical changes due to ageing or the 
underlying disease (Figs. 4A-B). Notably, cerebrospinal fluid (CSF) total volume becomes more strongly 
influencing PET (with PiB tracer) and CDR, while grey matter (GM) total volume decreased in influence. 
This may suggest that these could be important biomarkers for older cohorts. The Bayesian network 
models can then be used to guide the combination of factors with predisposing factors and biomarkers 
GM, CSF, PiB-PET, ApoE, and age.  Then a four-class (HC, very mild, mild, and moderate AD) 
classification was conducted. Various combinations of these data attributes were investigated, and 
some combinations obtained relatively high accuracy of identifying the AD class (Fig. 4C).  
 
    
 
Fig. 4. Bayesian network modeling identifies dynamical relationship and predisposing AD indicators and 
biomarkers. A,B. Bayesian networks (BNs) generated based on 133 participants at baseline (A), and at least one 
follow-up visit of the same participants during the M18-54 time interval (B). Thickness of arrows: strength of 
probabilistic influences between variables. Only time-evolved features are included (e.g. (ApoE) genotype was 
excluded). Cognitive and functional assessments considered were: mini-mental state examination (MMSE), 
logical memory immediate/delayed recall assessments (LMIR/LMDR), and clinical dementia rating (CDR); 
neuroimaging features: structural MRI’s total volume of grey matter (GM), cerebrospinal fluid (CSF), and 
positron-electron tomography (PET) with [11C]-Pittsburgh compound B (PiB) tracer. C. Data consisted of all 
available complete samples regardless of time point. Blue circle (red square): without (with) ApoE genotype. 
A B
C
Classification accuracy (area under the receiver operating characteristic (ROC) curve, AUC) of individual 
predisposing indicators and biomarkers and their combinations with respect to CDR, ranked based on AUC. 
Circled markers: BN models constructed using individual as well as combinations of predisposing 
factors/biomarkers without ApoE. Squared markers: BN models constructed using individual as well as 
combinations of predisposing factors/biomarkers with ApoE. The incorporation of ApoE into the BN structure 
generally improved the model performance. Adapted with permission from [16].  
 
 
With the availability of AI/ML-based, data-driven approaches, the route towards the development of 
automated clinical decision support systems (CDSS) [35] can be more readily laid out. For example, 
although most dementia diagnoses in clinical setting are based on categorical form, regression-based 
algorithms such as in [7] can provide CDSS with more graded information regarding disease stage (Fig. 
5). This can not only provide more refined information regarding disease stages but is also more in 
line with dementia progression as a continuous dynamic process rather than discrete “jumps” across 
categories of severity.  
 
 
 
Fig. 5. Portion of the graphical user interface of a computer-based clinical decision support system for predicting 
dementia severity of an individual patient. Left: Patient information panel; right: AD severity measurement scale 
with AD severity score (black line) and its confidence interval (grey range). Adapted with permission from [7].  
 
 
Conclusion 
 
We have discussed how neurological disorders such as neurodegeneration, particularly Alzheimer’s 
disease, could be studied with guidance from several computational approaches, which we grouped 
under the umbrella term Computational Neurology. The computational approaches can generally be 
classified under model-based or data-driven/AI; the former is used if sufficiently detailed and focused 
datasets are available while the latter under the conditions in which the data are large and 
heterogeneous. Overall, there remain many opportunities for researchers to link these two 
computational approaches (e.g. see [3]).  
 
The application of data-driven/AI in dementia research is still in its infancy, especially with regards to 
direct clinical applications. For the latter, sensitivity and specificity rates are especially important given 
the damaging consequences of misdiagnoses. Further, data-driven/AI approaches can readily lead to 
the development of automated clinical decision support systems. However, the latter are still not 
currently widely adopted in current dementia care pathways [29]. There are also challenges including 
their lack of pragmatism and realism for direct applications to frontline clinical settings. For example, 
some of the assessments in openly available datasets may not be used in clinical practice. Moreover, 
open datasets generally look “cleaner” than real-world data e.g. in electronic health/medical records. 
Perhaps deeper understanding of the needs and challenges of patients, clinicians and other 
stakeholders is needed to resolve these issues.  
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